DE602004025213D1 - Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen - Google Patents

Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen

Info

Publication number
DE602004025213D1
DE602004025213D1 DE602004025213T DE602004025213T DE602004025213D1 DE 602004025213 D1 DE602004025213 D1 DE 602004025213D1 DE 602004025213 T DE602004025213 T DE 602004025213T DE 602004025213 T DE602004025213 T DE 602004025213T DE 602004025213 D1 DE602004025213 D1 DE 602004025213D1
Authority
DE
Germany
Prior art keywords
solubilizing
production method
active substances
pharmacologically active
cyclodextrin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004025213T
Other languages
German (de)
English (en)
Inventor
Jacques Defaye
Carmen Ortiz-Mellet
Jose Manuel Garcia-Fernandez
Maria Gomez-Garcia
Kazimierz Chmurski
Jian-Xin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Centre National de la Recherche Scientifique CNRS
Universite Joseph Fourier Grenoble 1
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Universidad de Sevilla
Centre National de la Recherche Scientifique CNRS
Universite Joseph Fourier Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Universidad de Sevilla, Centre National de la Recherche Scientifique CNRS, Universite Joseph Fourier Grenoble 1 filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of DE602004025213D1 publication Critical patent/DE602004025213D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE602004025213T 2003-03-28 2004-03-22 Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen Expired - Lifetime DE602004025213D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0303899A FR2852959B1 (fr) 2003-03-28 2003-03-28 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour solubilisation de substances pharmacologiquement actives
PCT/FR2004/000691 WO2004087768A1 (fr) 2003-03-28 2004-03-22 Nouveaux derives de cyclodextrines, leur procede de preparation et leur utilisation notamment pour la solubilisation de substances pharmacologiquement actives

Publications (1)

Publication Number Publication Date
DE602004025213D1 true DE602004025213D1 (de) 2010-03-11

Family

ID=32947275

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025213T Expired - Lifetime DE602004025213D1 (de) 2003-03-28 2004-03-22 Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen

Country Status (9)

Country Link
US (2) US7632941B2 (enExample)
EP (1) EP1608687B1 (enExample)
JP (1) JP5054970B2 (enExample)
AT (1) ATE455795T1 (enExample)
CA (1) CA2520391C (enExample)
DE (1) DE602004025213D1 (enExample)
ES (1) ES2338558T3 (enExample)
FR (1) FR2852959B1 (enExample)
WO (1) WO2004087768A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001844A2 (en) 2004-01-29 2006-01-05 Pinnacle Pharmaceuticals β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN
US20080234182A1 (en) * 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
JP4976281B2 (ja) 2004-05-03 2012-07-18 オメガ バイオ‐ファーマ（アイ．ピー．３）リミテッド 代謝を調節するための材料および方法
AU2006211173A1 (en) 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. Beta-cyclodextrin derivatives as antibacterial agents
ES2294926B1 (es) * 2006-05-11 2009-02-16 Universidad De Sevilla Nuevos derivados de ciclodextrinas selectivamente funcionalizados en su cara secundaria, procedimiento de preparacion y utilizacion de los mismos.
FR2903987B1 (fr) * 2006-07-21 2012-12-21 Centre Nat Rech Scient Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
EP2328579B1 (en) * 2008-07-17 2013-10-23 The Johns Hopkins University Trioxane dimer sulfur compounds
US20100056475A1 (en) * 2008-08-06 2010-03-04 Alexander Chucholowski Cyclodextrin conjugates
CA2950610A1 (en) * 2014-05-29 2015-12-03 Uti Limited Partnership Cyclodextrin-based polyanionic and non-ionic dendrimers
CN109762042B (zh) * 2018-09-21 2022-04-08 河北艾克美冀生物科技有限公司 一种治疗癌症的药物、其合成方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2648464B1 (fr) * 1989-06-14 1991-08-30 Commissariat Energie Atomique Derives de cyclomalto-oligosaccharides et leurs procedes de preparation
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
US5959089A (en) * 1993-07-19 1999-09-28 Hannessian; Stephen Amino-cyclodextrin syntheses
FR2715307B1 (fr) * 1994-01-25 1996-04-05 Commissariat Energie Atomique Procédé de solubilisation dans un milieu aqueux d'agents antitumoraux de la famille du taxol, et cyclodextrines ramifiées utilisables pour cette solubilisation.
FR2716200B1 (fr) * 1994-02-11 1996-04-26 Commissariat Energie Atomique Procédé de préparation de cyclomaltooligosaccharides ramifiés, en particulier de cyclodextrines ramifiées.
FR2746103B1 (fr) * 1996-03-14 1998-07-24 Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6157642A (en) 1997-10-14 2000-12-05 Teledesic Llc Coding system and method for low-earth orbit satellite data communication
FI980489A7 (fi) * 1998-03-04 1999-09-05 Alexei Radievich Khomutov Syklodekstriinien uudet johdannaiset

Also Published As

Publication number Publication date
WO2004087768A1 (fr) 2004-10-14
US20070167401A1 (en) 2007-07-19
US20090264540A1 (en) 2009-10-22
US7632941B2 (en) 2009-12-15
FR2852959A1 (fr) 2004-10-01
CA2520391C (fr) 2012-11-20
ES2338558T3 (es) 2010-05-10
JP2006521440A (ja) 2006-09-21
US8440814B2 (en) 2013-05-14
CA2520391A1 (fr) 2004-10-14
JP5054970B2 (ja) 2012-10-24
FR2852959B1 (fr) 2008-02-15
ATE455795T1 (de) 2010-02-15
EP1608687A1 (fr) 2005-12-28
EP1608687B1 (fr) 2010-01-20

Similar Documents

Publication Publication Date Title
CY1105337T1 (el) Πρωτοτυπες διυδροπτepιδινονες, μεθοδος για την παραγωγη τους και η χρηση τους ως φαρμακευτικα μεσα
CY1108471T1 (el) Μεθοδος για την παραγωγη εστερων σκοπινης
CY1105994T1 (el) Aναδιαταγμενες πεντανολες, μεθοδος για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδων
ATE398125T1 (de) Chinazolin-derivate als tgf-beta-inhibitoren
CY1114564T1 (el) Μεθοδος για την παραγωγη διϋδροπτεριδινονων
DE602005014117D1 (de) Neues carbamyliertes epo und verfahren zu dessen herstellung
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE50208918D1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
DE602006010979D1 (de) Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CY1112630T1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ECSP045255A (es) Cumarinas utiles como biomarcadores
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
DE602004025213D1 (de) Neue cyclodextrinderivate, herstellungsverfahren dafür und verwendung davon zur solubilisierung von pharmakologisch wirksamen substanzen
ATE536354T1 (de) Neuartige 1-aza-bizykloalkyl-derivate für die behandlung psychotischer und neurodegenerativer störungen
MXPA05011962A (es) Oxiarenos substituidos.
ATE460419T1 (de) Organosiliciumverbindungen, ihre herstellung und ihre verwendung
TW200503686A (en) Cannabinoid receptor modulator
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
NO20034236D0 (no) Ny fremgangsmåte for den industrielle syntese av tetraestere av 5-[bis(karboksymetyl)amino]-3-karboksymetyl-4-cyano-2-tiofenkarboksylsyre, oganvendelse isyntesen av bivalente salter av ranelinsyre og deres hydrater
EA200401428A1 (ru) Способ получения цефдинира
DE60202565D1 (de) Einströmtür für einen Luftreiniger
ATE345326T1 (de) N-benzoylureido-zimts urederivate, verfahren zu deren herste llung und deren verwendung
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition